全文获取类型
收费全文 | 152574篇 |
免费 | 51565篇 |
国内免费 | 5820篇 |
专业分类
耳鼻咽喉 | 2105篇 |
儿科学 | 5062篇 |
妇产科学 | 1152篇 |
基础医学 | 22914篇 |
口腔科学 | 6546篇 |
临床医学 | 23056篇 |
内科学 | 32030篇 |
皮肤病学 | 8306篇 |
神经病学 | 16035篇 |
特种医学 | 4932篇 |
外国民族医学 | 35篇 |
外科学 | 20471篇 |
综合类 | 18252篇 |
现状与发展 | 17篇 |
一般理论 | 29篇 |
预防医学 | 11015篇 |
眼科学 | 3093篇 |
药学 | 15132篇 |
92篇 | |
中国医学 | 7072篇 |
肿瘤学 | 12613篇 |
出版年
2024年 | 304篇 |
2023年 | 1246篇 |
2022年 | 3119篇 |
2021年 | 5606篇 |
2020年 | 8415篇 |
2019年 | 13115篇 |
2018年 | 12497篇 |
2017年 | 13958篇 |
2016年 | 14226篇 |
2015年 | 15412篇 |
2014年 | 16268篇 |
2013年 | 16688篇 |
2012年 | 10494篇 |
2011年 | 10702篇 |
2010年 | 13836篇 |
2009年 | 9329篇 |
2008年 | 6592篇 |
2007年 | 5492篇 |
2006年 | 5296篇 |
2005年 | 4244篇 |
2004年 | 3622篇 |
2003年 | 3988篇 |
2002年 | 3656篇 |
2001年 | 3187篇 |
2000年 | 2395篇 |
1999年 | 1508篇 |
1998年 | 734篇 |
1997年 | 767篇 |
1996年 | 517篇 |
1995年 | 468篇 |
1994年 | 416篇 |
1993年 | 228篇 |
1992年 | 306篇 |
1991年 | 244篇 |
1990年 | 251篇 |
1989年 | 143篇 |
1988年 | 159篇 |
1987年 | 139篇 |
1986年 | 108篇 |
1985年 | 76篇 |
1984年 | 56篇 |
1983年 | 37篇 |
1982年 | 26篇 |
1981年 | 22篇 |
1980年 | 9篇 |
1979年 | 26篇 |
1978年 | 7篇 |
1977年 | 4篇 |
1974年 | 5篇 |
1966年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
社会力量具备相应的经济基础和技术条件,对于公立互联网医院体系建设具有积极的促进作用。但是实践中仍然存在商业模式不完善、监管制度不健全等问题。基于经济学契约理论要义,提出在坚持激励与约束机制并举、平衡公私益关系的前提下,通过完善医保政策、构建互联网医疗服务价格分类管理机制来促进社会力量向医疗服务公益性目标回归,并通过构建完善的监督体制来约束部分社会力量的盲目逐利性行为。 相似文献
3.
目的 应用可视化方法分析代谢组学在中医药领域的现状及趋势。方法 检索中国知网数据库(CNKI)和Web of Science 核心合集数据库2021年3月15日之前收录的中医药领域代谢组学研究的相关文献,应用CiteSpace软件对纳入的文献进行关键词、作者、研究机构等内容进行可视化分析。结果 共纳入中文文献247篇,英文文献350篇。文献数量在波动中迅速上升。中、英文文献作者合作网络显示,张爱华是中医药领域代谢组学研究发文量最多的作者,并形成了核心研究团队。发文机构显示,中国医学科学院是该领域的重要研究机构,机构间合作紧密。中、英文文献关键词分析显示,研究内容主要集中在核磁共振、代谢标记物、冠心病、质谱技术、代谢通路等相关领域。结论 中医药领域代谢组学研究的热点主要为中医药治疗代谢性疾病的机制研究。研究趋势为卵泡代谢组学研究及中药有效成分的研究。 相似文献
4.
目的了解何首乌致药物性肝损伤(Polygonum multiflorum-associated drug induce liver injury,PM-DILI)的临床病理学特点。方法收集2019年3月1日至2021年3月1日深圳市第三人民医院收治的8例PM-DILI患者临床资料。肝穿组织进行苏木素-伊红染色、网状纤维染色、Masson三色染色、铁、铜特殊染色和免疫组织化学染色,显微镜下观察分析。结果8例PM-DILI患者男女比为1∶1,平均年龄43岁,其中6例为急性PM-DILI,2例慢性为PM-DILI。入院血清学检查异常主要包括转氨酶升高和淤胆均为7例。主要组织病理学改变为点灶状坏死8例、界面炎5例、融合坏死4例,融合坏死以肝腺泡3带为主,不伴或伴少数炎细胞浸润;胆汁淤积5例,为肝腺泡3带的肝细胞、毛细胆管内淤胆,不伴或伴少数炎细胞浸润;中央静脉炎3例;病程长者可发生肝纤维化,甚至肝硬化2例。结论肝腺泡3带为主的急性淤胆和肝细胞坏死是PM-DILI主要组织学表现,严重者可发生静脉炎等血管损伤。 相似文献
5.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
6.
7.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
8.
目的 系统评价中药治疗哮喘-慢阻肺(ACO)的疗效与安全性。方法 全面检索PubMed、Cochrane Library、Web of Science、中国知网、万方、维普、中国医学文献数据库,纳入有关中医药治疗ACO的随机对照试验(RCT),运用Cochrane手册对纳入研究的方法学质量进行评估,采用Review Manager 5.3进行Meta分析。结果 共纳入32项RCT,包括2688例ACO患者,其中试验组1361例,对照组1327例。Meta分析结果显示,中医药可以显著改善ACO患者的中医证候疗效[RR=1.19,95% CI(1.13,1.25),P<0.00001]、CAT评分[MD=-3.62,95% CI(-4.37,-2.87),P<0.00001]、ACT评分[MD=3.42,95% CI(2.23,4.62),P<0.00001],、中医证候总积分[MD=-3.61,95% CI(-4.83,-2.39),P<0.00001]、FEV1[MD=0.59,95% CI(0.08,1.10),P=0.02]、FEV1%[MD=8.61,95% CI(5.20,12.1),P<0.00001]、FEV1/FVC[MD=6.52,95% CI(4.24,8.80),P<0.00001]、6 min步行实验[MD=41.18,95% CI(22.15,60.21),P<0.0001]、急性发作次数[MD=-2.46,95% CI(-3.62,-1.13),P<0.0001]。所有研究均未报道严重不良反应。结论 中药治疗ACO,可以显著提高临床疗效,改善患者的肺功能且具有较好安全性,但是需要更高质量、多样本、多中心的随机对照试验进一步确认。 相似文献
9.
目的:比较康莱特注射液联合紫杉醇及紫杉醇单纯化疗治疗晚期恶性胸腺瘤的不良反应和疗效。方法:2013年8月至2017年12月,经病理学和免疫组化确诊为恶性胸腺瘤并在我院肿瘤中心进行姑息性化疗的患者68例。康莱特注射液联合化疗为观察组(37例);单纯化疗为对照组(31例)。28天为一周期,共化疗4周期。结果:两组患者均无人发生过敏反应。观察组可有效减轻患者化疗不良反应:恶性、呕吐、四肢麻木、关节肌肉酸痛和白细胞下降(P<0.05),可以有效减轻患者胸闷症状和全身疼痛(P<0.05),在肿瘤控制方面,康莱特联合化疗的疗效较单纯化疗稍好,但均未见有统计学差异(P>0.05)。结论:康莱特注射液联合紫杉醇治疗晚期胸腺瘤,具有减轻患者疼痛、减轻化疗不良反应,从而提高患者化疗依从性的作用,值得临床进一步推广和研究。 相似文献
10.
Sung‐Hyun Hwang Myung‐Chul Kim Sumin Ji Yeseul Yang Yeji Jeong Yongbaek Kim 《Cancer science》2019,110(4):1256-1267
Metformin, a drug for type 2 diabetes mellitus, has shown therapeutic effects for various cancers. However, it had no beneficial effects on the survival rate of human malignant mesothelioma (HMM) patients. The present study was performed to elucidate the underlying mechanism of metformin resistance in HMM cells. Glucose‐starved HMM cells had enhanced resistance to metformin, demonstrated by decreased apoptosis and autophagy and increased cell survival. These cells showed abnormalities in mitochondria, such as decreased ATP synthesis, morphological elongation, altered mitochondrial permeability transition pore and hyperpolarization of mitochondrial membrane potential (MMP). Intriguingly, Mdr1 was significantly upregulated in mitochondria but not in cell membrane. The upregulated mitochondrial Mdr1 was reversed by treatment with carbonyl cyanide m‐chlorophenyl hydrazone, an MMP depolarization inducer. Furthermore, apoptosis and autophagy were increased in multidrug resistance protein 1 knockout HMM cells cultured under glucose starvation with metformin treatment. The data suggest that mitochondrial Mdr1 plays a critical role in the chemoresistance to metformin in HMM cells, which could be a potential target for improving its therapeutic efficacy. 相似文献